Shares of Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) have been given an average recommendation of “Buy” by the six ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $33.60.
ANVS has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Annovis Bio in a report on Tuesday, October 1st. EF Hutton Acquisition Co. I raised shares of Annovis Bio to a “strong-buy” rating in a research report on Tuesday, August 13th. Finally, Rodman & Renshaw restated a “buy” rating and issued a $67.00 price objective on shares of Annovis Bio in a research report on Tuesday, July 2nd.
Get Our Latest Analysis on Annovis Bio
Institutional Trading of Annovis Bio
Annovis Bio Stock Down 2.5 %
Shares of ANVS stock opened at $8.20 on Thursday. The firm has a market cap of $91.60 million, a P/E ratio of -1.43 and a beta of 1.72. The business has a 50-day moving average price of $8.52 and a two-hundred day moving average price of $8.84. Annovis Bio has a 12-month low of $4.53 and a 12-month high of $22.49.
Annovis Bio (NYSE:ANVS – Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.19. As a group, research analysts expect that Annovis Bio will post -2.53 EPS for the current fiscal year.
Annovis Bio Company Profile
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
Featured Stories
- Five stocks we like better than Annovis Bio
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- What Are the FAANG Stocks and Are They Good Investments?
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Energy and Oil Stocks Explained
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.